⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLYS News
Mineralys Therapeutics, Inc. Common Stock
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
globenewswire.com
MLYS
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
MLYS
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
globenewswire.com
MLYS
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
globenewswire.com
MLYS